51. Scleroderma Clinical trials / Disease details


Clinical trials : 523 Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCT2051200133
31/03/202112/02/2021A study of Guselkumab in Participants with Systemic SclerosisA Multicenter, Randomized, Placebo-controlled, Double-blind, Proof-of-concept Study of Guselkumab in Participants with Systemic Sclerosis Scleroderma, SystemicGroup A: Guselkumab Dose 1
Guselkumab Dose 1 will be administered intravenously.

Group A: Guselkumab Dose 2
Guselkumab Dose 2 will be administered subcutaneously.

Group B: Placebo
Placebo will be administered intravenously or subcutaneously.
Numaguchi HirotakaNULLRecruiting>= 18age old<= 75age oldBoth56Phase 2Japan
2NCT04683029
(ClinicalTrials.gov)
February 24, 202122/12/2020A Study of Guselkumab in Participants With Systemic SclerosisA Multicenter, Randomized, Placebo-controlled, Double-blind, Proof-of-concept Study of Guselkumab in Participants With Systemic SclerosisScleroderma, SystemicDrug: Guselkumab Dose 1;Drug: Guselkumab Dose 2;Drug: PlaceboJanssen Pharmaceutical K.K.NULLRecruiting18 Years75 YearsAll56Phase 2Japan